目的：对3例疑似自身免疫性血友病样凝血因子ⅩⅢ缺陷症（autoimmune haemorrhaphilia factor ⅩⅢ, AHⅩⅢ）患者进行检测, 明确其临床诊断、治疗及随访资料, 建立完整的AHⅩⅢ实验诊断流程。方法：收集3例AHⅩⅢ患者的临床信息, 通过氨释放法检测其凝血因子ⅩⅢ（factor ⅩⅢ, F ⅩⅢ）活性, 酶联免疫吸附试验（enzyme linked immunosorbent assay, ELISA）法检测F ⅩⅢ-A抗原（FⅩⅢ-A:Ag）、FⅩⅢ-B:Ag。抗FⅩⅢ抗体检测包括混合实验检测抗FⅩⅢ中和抗体的存在、Bethesda法测定抗FⅩⅢ抗体滴度、ELISA法检测抗FⅩⅢ-A亚基抗体等。结果：3例患者的尿素法FⅩⅢ定性试验均为阳性, FⅩⅢ活性<5%, FⅩⅢ-A:Ag<3%, FⅩⅢ-B:Ag分别为65.40%、116.28%、138.81%。3例患者混合实验均为阳性, Bethesda法测定抗FⅩⅢ中和抗体滴度分别为1.83 BU、1.67 BU、1.75 BU, 免疫法检测结果提示均存在抗FⅩⅢ-A亚基抗体。结论：建立了完整的ⅩⅢ的诊断流程, 并回顾了其诊断、治疗及预后相关文献。经诊断, 本研究3例患者均为低滴度抗FⅩⅢ-A亚基抗体导致的AHⅩⅢ。
Objective: To test and diagnose definitely three patients with suspected autoimmune hemophilia-like coagulation factor ⅩⅢ (AH ⅩⅢ) deficiency and establish a flowchart for the laboratory diagnosis of AH ⅩⅢ deficiency. Methods: The clinical data of these 3 patients were recorded. FⅩⅢ: Act was detected by ammonia release assay. F ⅩⅢ-A: Ag and F ⅩⅢ-B: Ag were assayed by ELISA. Laboratory mixing tests and Bethesda method were used to detect anti-F ⅩⅢ neutralizing antibody, and ELISA was used to detect the autoantibodies against F ⅩⅢ-A. Results: For the 3 patients, positive results were shown by ammonia release assay. FⅩⅢ: Act <5%, F ⅩⅢ-A: Ag <3% and FⅩⅢ-B: Ag were 65.40%, 116.28% and 138.81%, respectively. Laboratory mixing tests were positive in all the 3 patients, and Bethesda method revealed that the neutralizing antibody were 1.83 BU, 1.67 BU and 1.75 BU, respectively. Autoantibodies against F ⅩⅢ-A were detected by immunological assay in all the 3 patients. Conclusions: A flowchart for laboratory diagnosis of AH ⅩⅢ deficiency is established. All the 3 patients were diagnosed as AH ⅩⅢ deficiency caused by low titer autoantibodies against F ⅩⅢ-A. Relevant literature about the diagnosis, treatment and prognosis of AH ⅩⅢ deficiency is reviewed.
[1] Dorgalaleh A, Rashidpanah J.Blood coagulation factor ⅩⅢ and factor ⅩⅢ deficiency[J]. Blood Rev,2016,30(6):461-475.
[2] Levy JH, Greenberg C.Biology of Factor ⅩⅢ and clinical manifestations of Factor ⅩⅢ deficiency[J]. Transfusion,2013,53(5):1120-1131.
[3] Schroeder V, Kohler HP.Factor ⅩⅢ: Structure and Function[J]. Semin Thromb Hemost,2016,42(4):422-428.
[4] Komáromi I, Bagoly Z, Muszbek L, et al.Factor ⅩⅢ: novel structural and functional aspects[J]. J Thromb Haemost,2011,9(1):9-20.
[5] Dickneite G, Herwald H, Korte W, et al.Coagulation factor ⅩⅢ: a multifunctional transglutaminase with clinical potential in a range of conditions[J]. Thromb Haemost,2015,113(4):686-697.
[6] Muszbek L, Bereczky Z, Bagoly Z, et al.Factor ⅩⅢ: a coa-gulation factor with multiple plasmatic and cellular functions[J]. Physiol Rev,2011,91(3):931-972.
[7] Schroeder V, Kohler HP.New developments in the area of factor ⅩⅢ[J]. J Thromb Haemost,2013,11(2):234-244.
[8] Byrnes JR, Wolberg AS.Newly-Recognized Roles of Factor ⅩⅢ in Thrombosis[J]. Semin Thromb Hemost,2016,42(4):445-454.
[9] Kohler HP, Ichinose A, Seitz R, et al.Diagnosis and classification of factor ⅩⅢ deficiencies[J]. J Thromb Haemost,2011,9(7):1404-1406.
[10] Ichinose A, Japanese Collaborative Research Group (JCRG) on AH13 Hemorrhagic Acquired Coagulopathies.Inhibitors of Factor ⅩⅢ/13 in older patients[J]. Semin Thromb Hemost,2014,40(6):704-711.
[11] Ichinose A,Japanese Collaborative Research Group on AH13. Autoimmune acquired factor ⅩⅢ deficiency due to anti-factor ⅩⅢ/13 antibodies: A summary of 93 patients[J]. Blood Rev,2017,31(1):37-45.
[12] Muszbek L, Pénzes K, Katona é.Auto- and alloantibodies against factor ⅩⅢ: laboratory diagnosis and clinical consequences[J]. J Thromb Haemost,2018,16(5):822-832.
[13] Tone KJ, James TE, Fergusson DA, et al.Acquired Factor ⅩⅢ Inhibitor in Hospitalized and Perioperative Patients: A Systematic Review of Case Reports and Case Series[J]. Transfus Med Rev,2016,30(3):123-131.
[14] Souri M, Osaki T, Ichinose A, et al.Anti-factor ⅩⅢ A subunit (F ⅩⅢ-A) autoantibodies block FⅩⅢ-A2 B2 assembly and steal F ⅩⅢ-A from native F ⅩⅢ-A2 B2[J]. J Thromb Haemost,2015,13(5):802-814.
[15] Ajzner E, Schlammadinger A, Kerényi A, et al.Severe bleeding complications caused by an autoantibody against the B subunit of plasma factor ⅩⅢ: a novel form of acquired factor ⅩⅢ deficiency[J]. Blood, 2009,113(3):723-725.
[16] Boehlen F, Casini A, Chizzolini C, et al.Acquired factor ⅩⅢ deficiency: a therapeutic challenge[J]. Thromb Haem-ost,2013,109(3):479-487.
[17] Muszbek L, Katona é.Diagnosis and Management of Congenital and Acquired F ⅩⅢ Deficiencies[J]. Semin Thromb Hemost,2016,42(4):429-439.
[18] Katona é, Pénzes K, Molnár é, et al.Measurement of factor ⅩⅢ activity in plasma[J]. Clin Chem Lab Med,2012, 50(7):1191-1202.
[19] Kessel R, Hu C, Shore-Lesserson L, et al.A child with acquired factor ⅩⅢ deficiency: case report and literature review[J]. Haemophilia, 2013,19(6):814-826.
[20] Osaki T, Sugiyama D, Magari Y, et al.Rapid immunochromatographic test for detection of anti-factor ⅩⅢ A subunit antibodies can diagnose 90% of cases with autoimmune haemorrhaphilia ⅩⅢ/13[J]. Thromb Haemost,2015,113(6):1347-1356.
[21] Franchini M, Mannucci PM.Acquired haemophilia A: a 2013 update[J]. Thromb Haemost,2013,110(6):1114-1120.
[22] Christiansen J, Kahn R, Schmidtchen A, et al.Idiopathic angioedema and urticarial vasculitis in a patient with a history of acquired haemophilia[J]. Acta Derm Venereol,2015,95(2):227-228.
[23] Cohen JI.Cinical practice: Herpes zoster[J]. N Engl J Med,2013,369(3):255-263.
[24] de Jager T, Pericleous L, Kokot-Kierepa M, et al. The burden and management of F ⅩⅢ deficiency[J]. Haemophilia,2014,20(6):733-740.
[25] Inbal A, Oldenburg J, Carcao M, et al.Recombinant factor ⅩⅢ: a safe and novel treatment for congenital factor ⅩⅢ deficiency[J]. Blood, 2012,119(22):5111-5117.
